|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125131 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-21 15:40:36 |
|
注册时间: Date of Registration: |
2026-05-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于负荷CT心肌灌注技术联合CT- FFR评价阻塞性冠心病患者心肌微循环功能 |
|
Public title: |
Evaluation of myocardial microcirculation function in patients with obstructive coronary artery disease using load-based CT myocardial perfusion imaging combined with CT-FFR |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于负荷CT心肌灌注技术联合CT- FFR评价阻塞性冠心病患者心肌微循环功能 |
|
Scientific title: |
Evaluation of myocardial microcirculation function in patients with obstructive coronary artery disease using load-based CT myocardial perfusion imaging combined with CT-FFR |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曲晓峰 |
研究负责人: |
曲晓峰 |
|
Applicant: |
Xiaofeng Qu |
Study leader: |
Xiaofeng Qu |
|
申请注册联系人电话: Applicant telephone: |
+86 177 0987 5118 |
研究负责人电话:
Study leader's |
+86 177 0987 5118 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
drquxiaofeng@163.com |
研究负责人电子邮件: Study leader's E-mail: |
drquxiaofeng@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
辽宁省大连市沙河口区中山路467号 |
研究负责人通讯地址: |
辽宁省大连市沙河口区中山路467号 |
|
Applicant address: |
No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province |
Study leader's address: |
No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
大连医科大学附属第二医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Dalian Medical University |
||
|
研究负责人所在单位: |
大连医科大学附属第二医院放射科 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Dalian Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2026-088-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
大连医科大学附属第二医院伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of the Second Hospital of Dalian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-09 00:00:00 | ||
|
伦理委员会联系人: |
韩璐璐 |
||
|
Contact Name of the ethic committee: |
Lulu Han |
||
|
伦理委员会联系地址: |
辽宁省大连市沙河口区中山路 467 号 |
||
|
Contact Address of the ethic committee: |
No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 411 8467 1291 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
dy2ylunli@163.com |
|
研究实施负责(组长)单位: |
大连医科大学附属第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Dalian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省大连市沙河口区中山路467号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-financing |
||||||||||||||||||||||
|
研究疾病: |
阻塞性冠心病 |
||||||||||||||||||||||
|
Target disease: |
Obstructive coronary heart disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本课题拟通过动态CT心肌灌注技术一站式获取CT-FFR、心肌灌注参数,实现阻塞性冠心病患者形态和心肌微循环功能的一站式评价。量化分析负荷态CT-FFR与静息态CT-FFR的数值差异及分布特征,明确两种状态下CT-FFR差异与心肌灌注参数(MBF等)的相关性 |
||||||||||||||||||||||
|
Objectives of Study: |
This project aims to obtain CT-FFR and myocardial perfusion parameters in a one-stop manner through dynamic CT myocardial perfusion technology, thereby achieving a one-stop evaluation of the morphology and myocardial microcirculation function of patients with obstructive coronary heart disease. Quantitative analysis will be conducted on the numerical differences and distribution characteristics between the loaded-state CT-FFR and the resting-state CT-FFR, and the correlation between the differences in CT-FFR in the two states and myocardial perfusion parameters (such as MBF, etc.) will be clarified. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.影像资料和临床病史资料完整;2.18-80岁;3.临床怀疑阻塞性冠心病;4. 冠脉非左主干狭窄程度>70%和(或)左主干>50%. |
||||||||||||||||||||||
|
Inclusion criteria |
1.Complete imaging data and clinical history data; 2. Age range of 18 to 80 years old; 3. Clinically suspected of obstructive coronary heart disease; 4. Coronary artery non-left main stenosis degree > 70% and/or left main > 50% |
||||||||||||||||||||||
|
排除标准: |
1.急性冠脉综合征、心衰、不稳定性心绞痛; 2.服用过抗焦虑、抗抑郁等精神类药物; 3.严重肾功能异常; 4.碘媒对比剂过敏; 5.无法进行负荷心肌灌注(II-III度房室传导阻滞、窦房结功能障碍); 6.任何非左主干狭窄程度<70%和(或)左主干<50% |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Acute coronary syndrome, heart failure, unstable angina pectoris; 2. Have taken psychotropic drugs such as anti-anxiety and anti-depression drugs; 3. Severe renal dysfunction; 4. Allergy to iodine-based contrast agents; 5.Unable to perform stress myocardial perfusion (second- and third-degree atrioventricular block, sinus node dysfunction) ; 6. Any non-left main coronary stenosis less than 70% and/or left main coronary stenosis less than 50% |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-01 00:00:00至 To 2027-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2026-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究不共享受试者个体原始数据(IPD) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study does not share the individual raw data (IPD) of the participants. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用标准化病例记录表(Case Report Form, CRF) 设计数据采集方案,由经过培训的研究人员严格按照研究方案,提取并记录受试者的基线临床资料、影像学检查结果、实验室检验指标及随访信息;数据录入采用双人独立双录入方式,通过交叉核对完成数据一致性校验,确保数据准确性;所有数据存储于本单位加密科研服务器,由专职数据管理员负责数据管理与质量控制,严格遵循数据安全与隐私保护相关规范,保障数据的完整性、可追溯性。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study adopted a standardized case report form (CRF) to design the data collection plan. Trained researchers strictly followed the research plan to extract and record the baseline clinical data, imaging examination results, laboratory test indicators, and follow-up information of the subjects. Data entry was conducted using a double-independent double-entry method, and data consistency verification was completed through cross-checking to ensure data accuracy. All data were stored on the unit's encrypted research server, and a dedicated data administrator was responsible for data management and quality control. Strict adherence to relevant data security and privacy protection norms was ensured to guarantee the integrity and traceability of the data. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |